SCHEMBL6345951

SCHEMBL6345951

CCc1nc(Cl)c(CC)nc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.41
HTT P42858 1/20 0.41
CRHR1 P34998 5/20 0.32
LMNA P02545 2/20 0.32
MEN1 O00255 1/20 0.32
SLC22A1 O15245 1/20 0.32
ALDH1A1 P00352 1/20 0.32
DHFR P00374 1/20 0.32
TP53 P04637 1/20 0.32
CYP1A2 P05177 1/20 0.32
HEXA P06865 1/20 0.32
HEXB P07686 1/20 0.32
CYP3A4 P08684 1/20 0.32
HTR1A P08908 1/20 0.32
ADRA2A P08913 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
HTR2A P28223 1/20 0.32
ADRA1A P35348 1/20 0.32
HTR2B P41595 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9807051 0.94 GLA (0.38) GLAHTTCRHR1LMNAMEN1
SCHEMBL14734330 0.77 HTT (0.36) GLAHTTLMNAALDH1A1SMN1; SMN2
SCHEMBL10009532 0.75 TDP1 (0.58) LMNAMEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL11093101 0.75 HTT (0.43) GLAHTTLMNAMEN1ALDH1A1
SCHEMBL282741 0.74 GLA (0.42) GLAHTTLMNAALDH1A1
SCHEMBL10126757 0.74
SCHEMBL29452951 0.74 GLA (0.42) GLAHTTLMNAALDH1A1
SCHEMBL11155328 0.73 TDP1 (0.41) GLAHTTCRHR1LMNAMEN1
SCHEMBL282566 0.72 POLB (0.35) GLAHTTLMNAMEN1SLC22A1
SCHEMBL29452887 0.72 POLB (0.35) GLAHTTLMNAMEN1SLC22A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050176721-A1 2,5-Diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylprimidines HUANG JIANHUA (US) 2005-08-11 US disclosed
US-6887875-B2 Bind with high selectivity and/ or high affinity to CRF1 receptors (Corticotropin Releasing Factor 1 Receptors), useful for treating psychiatric and neurological diseases, including depression, anxiety and post trauma stress NEUROGEN CORPORATION (US) 2005-05-03 US disclosed
EP-1399428-A1 2,5-DIARYLPYRAZINES, 2,5-DIARYLPYRIDINES AND 2,5-DIARYLPYRIMIDINES AS CRF1 RECEPTOR MODULATORS Neurogen Corporation (US) 2004-03-24 EP disclosed
US-20030119844-A1 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines NEUROGEN CORPORATION 2003-06-26 US disclosed
WO-2002100838-A1 2,5-DIARYLPYRAZINES, 2,5-DIARYLPYRIDINES AND 2,5-DIARYLPYRIMIDINES AS CRF1 RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2002-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119844-A1 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines CRHR2, CRHR1, CRH GLA 4808/4885HTT 1676/4885CRHR1 2/4885
US-20050176721-A1 2,5-Diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylprimidines CRHR2, CRHR1, CRH GLA 4796/4885HTT 1639/4885CRHR1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.